BOOK
PET Imaging of Lymphoma, An Issue of PET Clinics - E-Book
Rebecca Elstrom | Stephen Schuster
(2012)
Additional Information
Book Details
Abstract
This issue provides a complete update on PET imaging of lymphoma, starting with a clinical assessment of lymphoma and the role of medical imaging. The role of structural imaging in lymphoma is then discussed. From a Nuclear Medicine perspective, FDG-PET in lymphoma is reviewed, as is the role of FDG-PET in pediatric lymphoma. Next, the role of non-FDG tracers in lymphoma is reviewed. Other articles cover the role of fMRI and optical imaging in lymphoma, the role of diffusion-weighted MRI in lymphoma, FDG-PET in personalization of therapy in patients with lymphoma, and PET and radiation oncology in lymphoma.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| PET Imaging of Lymphoma: PET Clinics | i | ||
| Copyright Page | ii | ||
| Table of Contents | vii | ||
| Contributors | iii | ||
| Preface: PET Imaging of Lymphoma | xiii | ||
| Chapter 1. Role of Structural Imaging in Lymphoma | 1 | ||
| STAGING AND RESPONSE ASSESSMENT IN LYMPHOMA | 1 | ||
| GROWTH AND DISTRIBUTION PATTERNS OF HL AND NHL | 1 | ||
| ROLE OF CROSS-SECTIONAL STRUCTURAL IMAGING IN LYMPHOMA | 2 | ||
| CROSS-SECTIONAL STRUCTURAL IMAGING MODALITIES IN LYMPHOMA: GENERAL CONSIDERATIONS CT | 4 | ||
| USEFULNESS OF CT AND MR IMAGING (AND US) IN SEVERAL BODY REGIONS | 7 | ||
| ADVANCED CT, MR IMAGING, AND US TECHNIQUES | 12 | ||
| SUMMARY | 16 | ||
| REFERENCES | 16 | ||
| Chapter 2. FDG-PET in Lymphoma: Nuclear Medicine Perspective | 21 | ||
| INITIAL STAGING | 22 | ||
| FDG-PET IN END-TREATMENT RESPONSE ASSESSMENT | 24 | ||
| PET FOR FOLLOW-UP OF LYMPHOMA | 28 | ||
| PET FOR RESPONSE PREDICTION BEFORE HIGH-DOSE SALVAGE THERAPY | 28 | ||
| SUMMARY | 29 | ||
| REFERENCES | 29 | ||
| Chapter 3. The Evolving Role of Medical Imaging in Lymphoma Management: The Clinician’s Perspective | 35 | ||
| INTRODUCTION TO LYMPHOMAS | 35 | ||
| DIAGNOSIS: THE ROLE OF IMAGING | 37 | ||
| STAGING: IMAGING OPTIONS | 37 | ||
| ASSESSMENT OF BONE MARROW INVOLVEMENT BY IMAGING | 40 | ||
| INTERIM IMAGING DURING THERAPY | 40 | ||
| ASSESSMENT OF RESIDUAL MASSES | 41 | ||
| FOLLOW-UP AFTER FINISHING TREATMENT AND MONITORING FOR RELAPSE | 41 | ||
| FUTURE ROLE OF IMAGING IN MANAGEMENT OF LYMPHOMAS | 42 | ||
| REFERENCES | 42 | ||
| Chapter 4. Review of Clinical Applications of Fluorodeoxyglucose-PET/Computed Tomography in Pediatric Patients with Lymphoma | 47 | ||
| PET/CT FOR INITIAL STAGING | 47 | ||
| PET/CT FOR INTERIM AND POSTTHERAPY STUDIES | 49 | ||
| PET/CT FOR EVALUATION OF NODAL AND EXTRANODAL DISEASE | 51 | ||
| FDG-PET/CT IN EVALUATION OF NODAL LESIONS | 51 | ||
| FDG-PET/CT IN EVALUATION OF EXTRANODAL LESIONS | 52 | ||
| ASSOCIATED INFLAMMATORY/INFECTIOUS FINDINGS | 54 | ||
| SUMMARY | 54 | ||
| REFERENCES | 55 | ||
| Chapter 5. Role of Positron Emission Tomography with Fludeoxyglucose F 18 in Personalization of Therapy in Patients with Lymphoma | 57 | ||
| CURRENT LEVEL OF EVIDENCE DLBCL | 57 | ||
| HL | 60 | ||
| OTHER LYMPHOMA SUBTYPES: RECENT HIGHLIGHTS | 62 | ||
| RECOMMENDATIONS | 63 | ||
| REFERENCES | 63 | ||
| Chapter 6. The Use of PET in Radiation Therapy for Lymphoma | 67 | ||
| CAN FDG-PET RESPONSE BE USED TO OMIT CONSOLIDATIVE RADIATION? | 67 | ||
| FDG-PET/CT IN RADIATION TREATMENT PLANNING FOR LYMPHOMA | 68 | ||
| SUMMARY | 71 | ||
| DOES RADIATION INTERFERE WITH EARLY INTERVAL FDG-PET SCANNING? | 71 | ||
| REFERENCES | 71 | ||
| Chapter 7. Evolving Importance of Diffusion-Weighted Magnetic Resonance Imaging in Lymphoma | 73 | ||
| CURRENT ROLE OF IMAGING IN LYMPHOMA | 73 | ||
| 18F-FLUORODEOXYGLUCOSE PET/COMPUTED TOMOGRAPHY | 73 | ||
| WHOLE-BODY MAGNETIC RESONANCE IMAGING | 74 | ||
| BASICS OF (WHOLE-BODY) DWI | 74 | ||
| WHOLE-BODY DIFFUSION-WEIGHTED IMAGING | 74 | ||
| DEVELOPMENT OF WHOLE-BODY DWI | 75 | ||
| GENERAL CHALLENGES ASSOCIATED WITH THE EVALUATION OF WHOLE-BODY DWI | 76 | ||
| WHOLE-BODY DWI FOR THE STAGING OF LYMPHOMA | 77 | ||
| WHOLE-BODY DWI FOR THERAPY RESPONSE ASSESSMENT IN LYMPHOMA | 78 | ||
| SUMMARY | 80 | ||
| REFERENCES | 80 | ||
| Chapter 8. Novel PET Radiotracers for Potential Use in Management of Lymphoma | 83 | ||
| IMAGING TUMOR PROLIFERATION | 83 | ||
| SUMMARY | 94 | ||
| IMAGING TUMOR HYPOXIA | 95 | ||
| FMISO versus Cu-ATSM | 96 | ||
| SUMMARY | 99 | ||
| IMAGING TUMOR ANGIOGENESIS | 99 | ||
| SUMMARY | 103 | ||
| IMAGING APOPTOSIS | 103 | ||
| SUMMARY | 106 | ||
| IMAGING AMINO ACID METABOLISM | 106 | ||
| Chapter 9. Prediction and Early Detection of Response by NMR Spectroscopy and Imaging | 119 | ||
| ACKNOWLEDGMENTS | 125 | ||
| REFERENCES | 125 | ||
| Chapter 10. Diffuse Optical Technology: A Portable and Simple Method for Noninvasive Tissue Pathophysiology | 127 | ||
| REFERENCES | 130 | ||
| Index | 133 |